Case Report Pyoderma gangrenosum is an inflammatory disease of unknown etiology that primarily affects adults and consists of renewed destructive ulcers.

Case Report

Pyoderma gangrenosum is an inflammatory disease of unknown etiology that primarily affects adults and consists of renewed destructive ulcers.1 Several variants have been identified, with typical lesions having inflamed, undermined borders. Management includes a combination of local and systemic modalities.2 For small gatherings whirlpool baths, topical antibacterials, and topical steroids are usually sufficient. Immunosuppressive and cytotoxic agents have been give employment toed in moderate to severe cases. In a cases, the ulcerative process can become extensive and recalcitrant, adversely affecting a patient's medical condition.

CASE REPORT

A 57-year-old woman with pyoderma gangrenosum confirmed through biopsy and a history of hypertension and chronic renal insufficiency quick in emergenciesed with a lower left extremity imposthume of 3 years' duration that had failed to heal with conventional pang care and elevation. Due to progressive ulceration, the patient experienced significant fluid and electrolyte losse that exacerbated her underlying renal condition. periodical infections led to sepsis, requiring hospital admission for intravenous antibiotic administration. After unhappy trials of hyperbaric oxygen, immunosuppressive therapy, anti-infectives, and surgical debridement with occlusive dressings, below-the-knee amputation was attract favor toed (Figure 1).

After surgical debridement, a 410 cm^sup 2^ circumferential, fullthickness pliable tissue defect remained over the distal left leg and ankle. Recombinant human platelet-derived development factor-BB (becaplermin gel [Regranex; Ortho-McNeil, Raritan, NJ]) was applied one time daily to the wound and secreteed with moist saline gauze that was changed twice daily. Although the sustenance and Drug Administration approved becaplermin for the treatment of lower extremity diabetic neuropathic festers there is no legal contraindication to prescribing becaplermin in nondiabetic patients. Off-label applications are left to the clinician's medical long head in treating each patient's specific condition.

Eight weeks after initiating becaplermin therapy, granulation germs were noted in the delicate tissue and over the expos tendons and bone (Figure 2) After 12 weeks, the connective tissue constitutions were completely covered by a healthy bed of granulation tissue (Figure 3) In this case, the dangers associated with obtaining autogenous tissue to raise reepithelization necessitated the use of a meshed allograft. The grafts healed uneventfully; thorough wound closure was achieved 8 weeks following allograft placement (Figure 4) The patient regained sated functional use of the lower extremity and has since maintained skin integrity and remained infection-free.

DISCUSSION

Pyoderma gangrenosum is a chronic and ulcerative condition of the skin that can take several forms, including pustular, bullous, ulcerative, and peristomal variants. Treatment should be tailored to the patients symbol of lesion, the extent and duration of disease, other associated systemic diseases, age, form relative to sex and prior treatment.3 Topical antibacterial and anti-inflammatory medications are usually effective for treating limited disease, while systemic therapy may be required for more hard and widespread disease. Systemic therapies include puls steroids, antibiotics, and in-imunosuppressive agents like as cyclosporine, methotrexate, chlorambucil, and granulocytemacrophage colony-stimulating factor.4 one ulcers become recalcitrant and current serious threats to a patients well-being. Restoring the subcutaneous tissue to defend the exposed connective tissue, improving the environment for reepithelization, and imposing an environmental barrier is critical for managing these pain s

In this case, plain pyoderma gangrenosum ulcerations created circumferential in all senses of connective tissue structures vital to limb integrity. It was theorized that accelerated hurt healing via the chemotactic recruitment and proliferation of reparative small rooms by exogenous plateletderived growth factor-BB (becaplermin) would be beneficial. Becaplermin has been shown to accelerate anguish healing and increase the incidence of total healing of lower extremity diabetic ulcers56

After treatment with becaplermin, granulation tissue formation was seen in this torture Becaplermin induced granulation that screened the vital structures and optimized the plastic tissue bed. Use of becaplermin and allograft placement l to auspicious wound closure, resulting in limb preservation and resumption of the patients normal activities of living. It is believed that becaplermin could be used in other cases of pyoderma gangrenosum, based in succession the positive results of this case.

REFERENCE

1 Powell R Holbrook ME Steven A. Pyoderma gangrenosum and its treatment. Lancet 1997;350:1720-1

2 Powell FC Su WP Perry HO Pyoderma gangrenosum: clarification and management. J Am Acad Dermatol 1996;34:395-409

3Trent J Kirsner R Diagnosing pyoderma gangrenosum. Adv Skin damage Care 2001;14:151-3.